Every ureteral stent placed in the urinary tract exists in a mineral-rich fluid environment, and over time that environment can work against the device itself through a process called encrustation. Ureteral stent encrustation refers to the gradual accumulation of calcium, phosphate, and other mineral salts on the stent's inner and outer surfaces, and it is one of the central engineering challenges manufacturers address through material selection and surface coating technology. This article explains what drives encrustation at a material science level and how design choices such as phosphorylcholine coatings are intended to address it.
What Actually Causes Mineral Buildup on a Stent Surface?
Urine is a complex solution containing dissolved minerals, proteins, and cellular debris, and under certain conditions — including urine pH, mineral concentration, and how long a foreign surface sits in contact with it — these components can precipitate out and adhere to an indwelling device. On a microscopic level, encrustation tends to begin with the adsorption of proteins and a thin conditioning film onto the stent surface, which then provides a scaffold for mineral crystals, particularly calcium oxalate and calcium phosphate, to nucleate and grow. Once initiated, encrustation is generally reported to progress more rapidly, since the existing crystal surface offers additional nucleation sites for further mineral deposition. Longer indwelling time is a well-established risk factor for greater encrustation, which is part of why physicians plan stent exchange schedules rather than leaving any stent in place indefinitely.
How Does Biofilm Formation Relate to Encrustation?
Biofilm is a structured community of bacteria embedded in a self-produced protective matrix that can form on almost any indwelling medical device left in contact with a fluid environment containing microorganisms, including ureteral stents. Biofilm formation and encrustation are commonly reported to be interrelated processes: bacteria within a biofilm can produce enzymes, such as urease, that alter local urine chemistry in ways that promote mineral crystallization, while existing mineral deposits can in turn create a rougher surface that is more hospitable to bacterial adhesion. This relationship means that strategies aimed at reducing one process often have a meaningful effect on the other, which is why stent surface engineering commonly targets both bacterial adhesion and mineral nucleation simultaneously rather than treating them as separate problems.
What Is Phosphorylcholine Coating and Why Is It Used on Stents?
Phosphorylcholine (PC) is a molecule that mimics the outer structure of natural cell membranes, and coatings based on it are used across various medical device categories as a way to create a more biologically inert, hydrophilic surface layer. When applied as a surface treatment to a ureteral stent, a phosphorylcholine coating is generally intended to reduce the initial adsorption of proteins and other biological material onto the stent surface — the conditioning film that typically precedes both encrustation and biofilm formation. By making the surface less receptive to this initial adsorption step, a PC coating is positioned by manufacturers as a way to help address mineral buildup and support patient comfort over an extended indwelling period, compared with an uncoated stent surface. It is important to note that no stent coating eliminates encrustation risk entirely, and regular monitoring and scheduled exchange remain part of standard stent management regardless of surface treatment.
Material Choice as a Complementary Strategy to Surface Coating
Beyond surface coatings, the base polymer of a stent itself contributes to overall performance. Polyurethane (PUR) is a commonly used ureteral stent material valued for its flexibility and biocompatibility profile. The UroFlow Ureteral Stents manufactured by INVAMED are constructed from polyurethane and are offered with an optional phosphorylcholine surface treatment, an approach the manufacturer describes as aimed at minimal encrustation, patient comfort, and suitability for longer-term indwelling use. Selecting an appropriate stent material and coating combination for a given patient is a decision made by the treating physician based on the clinical indication and anticipated indwelling duration. Further detail is available on the UroFlow Ureteral Stents page, alongside the broader urology and incontinence management category.
Does a longer-lasting stent coating mean the stent can stay in longer without follow-up?
No. Even stents designed to help address encrustation over extended indwelling periods still require the monitoring and exchange schedule set by the treating physician. Coating technology is intended to support performance during the planned indwelling period, not to replace scheduled clinical follow-up.
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.